Literature DB >> 2756244

Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases.

N Chiannilkulchai1, Z Driouich, J P Benoit, A L Parodi, P Couvreur.   

Abstract

Free doxorubicin and doxorubicin associated with polyisohexlycyanoacrylate were tested for their therapeutic efficiency in hepatic metastasis-bearing mice. The metastases originated from the M 5076 reticulum cell sarcoma. Irrespective of the dose and the administration schedule, the reduction of the number of metastases was much larger with the doxorubicin-loaded nanoparticles than with free doxorubicin. This was clearly confirmed by histological examination. Although pharmacological and pharmacokinetic data indicated a strong capture of the nanoparticles by the hepatic issue, the mechanism of nanoparticle therapeutic efficiency remains unclear.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2756244     DOI： 10.1089/sct.1989.5.1

Source DB:  PubMed          Journal:  Sel Cancer Ther        ISSN： 1043-0733


  12 in total

Review 1.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

2.  Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages.

Authors:  C E Soma; C Dubernet; G Barratt; F Nemati; M Appel; S Benita; P Couvreur
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

3.  Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.

Authors:  G Schwab; C Chavany; I Duroux; G Goubin; J Lebeau; C Hélène; T Saison-Behmoaras
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

4.  Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice.

Authors:  N Chiannilkulchai; N Ammoury; B Caillou; J P Devissaguet; P Couvreur
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles.

Authors:  J Kattan; J P Droz; P Couvreur; J P Marino; A Boutan-Laroze; P Rougier; P Brault; H Vranckx; J M Grognet; X Morge
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

6.  Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles.

Authors:  F Lescure; C Seguin; P Breton; P Bourrinet; D Roy; P Couvreur
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

7.  Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides.

Authors:  C Chavany; T Le Doan; P Couvreur; F Puisieux; C Hélène
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

8.  Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)/CD34(+) aptamer.

Authors:  M A Zaimy; A Jebali; B Bazrafshan; S Mehrtashfar; S Shabani; A Tavakoli; S H Hekmatimoghaddam; A Sarli; H Azizi; P Izadi; B Kazemi; A Shojaei; A Abdalaian; J Tavakkoly-Bazzaz
Journal:  Cancer Gene Ther       Date:  2016-08-12       Impact factor: 5.987

9.  A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer.

Authors:  Kishore Golla; Cherukuvada Bhaskar; Farhan Ahmed; Anand K Kondapi
Journal:  J Cancer       Date:  2013-09-14       Impact factor: 4.207

10.  Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats.

Authors:  Kishore Golla; Bhaskar Cherukuvada; Farhan Ahmed; Anand K Kondapi
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.